Literature DB >> 35137377

SARS-CoV-2 Liability: The Hidden Mystery Behind Its Presentation in Children.

Reza Jafarzadeh Esfehani1, Mohammad Hassan Aelami2, Afsaneh Rezaei Kalat3, Saman Soleimanpour4, Zahra Pasdar5, Majid Khazaei4, Alireza Pasdar6,7,8,9,7, Amir Avan10,11.   

Abstract

Coronavirus disease 2019 (COVID-19) is now of global concern because of its rapid dissemination across the globe. It is unclear whether COVID-19 is as hazardous as previous coronavirus outbreaks, though there are many overlapping similarities between these viruses. An important similar feature includes the virus's pathogenicity in pediatric populations. Additionally, genetic factors are recognized as important contributors to infectious disease susceptibility. Further understanding of this area can help make sense of the pathogenesis of COVID-19 and the varying clinical spectrums of the disease. The available data suggests that COVID-19 most likely produces mild symptoms in a healthy pediatric population regardless of their age, and recovery appears to occur without serious sequelae in the vast majority. However, the available data regarding the detailed repercussions of COVID-19 in children is very limited. To date, only some theoretical issues could be responsible for the COVID-19 susceptibility in pediatric patients, including a more intact but mature immune system within the respiratory system, possible role of viral interference in pediatric populations that are more often infected with common respiratory viruses, possible role of gut-lung axis, and a respiratory system with different amounts of cellular receptors for COVID-19 virus. Moreover, there is little data available on the genetic risk factors for COVID-19, and future research should aim to cover this gap in knowledge. This chapter aims to summarize the recently published data on the impact of COVID-19 in the pediatric population and to systematically review the available evidence of genetic risk factors for COVID-19.
© 2021. The Author(s), under exclusive license to Springer Nature Switzerland AG.

Entities:  

Keywords:  Immune system; Pediatrics; Severe acute respiratory syndrome coronavirus 2

Mesh:

Year:  2021        PMID: 35137377     DOI: 10.1007/978-3-030-85113-2_13

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  26 in total

1.  Microbiota regulates immune defense against respiratory tract influenza A virus infection.

Authors:  Takeshi Ichinohe; Iris K Pang; Yosuke Kumamoto; David R Peaper; John H Ho; Thomas S Murray; Akiko Iwasaki
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-14       Impact factor: 11.205

2.  Observational study on immune response to yellow fever and measles vaccines in 9 to 15-month old children. Is it necessary to wait 4 weeks between two live attenuated vaccines?

Authors:  R Michel; F Berger; J Ravelonarivo; P Dussart; M Dia; M Nacher; S Rogier; D Moua; F D Sarr; O M Diop; A A Sall; L Baril
Journal:  Vaccine       Date:  2015-04-02       Impact factor: 3.641

3.  ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia.

Authors:  Hong Peng Jia; Dwight C Look; Lei Shi; Melissa Hickey; Lecia Pewe; Jason Netland; Michael Farzan; Christine Wohlford-Lenane; Stanley Perlman; Paul B McCray
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

Review 4.  Severe acute respiratory syndrome (SARS) in neonates and children.

Authors:  A M Li; P C Ng
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2005-11       Impact factor: 5.747

Review 5.  Is chickenpox so bad, what do we know about immunity to varicella zoster virus, and what does it tell us about the future?

Authors:  Anne A Gershon
Journal:  J Infect       Date:  2017-06       Impact factor: 6.072

6.  TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein.

Authors:  Adeline Heurich; Heike Hofmann-Winkler; Stefanie Gierer; Thomas Liepold; Olaf Jahn; Stefan Pöhlmann
Journal:  J Virol       Date:  2013-11-13       Impact factor: 5.103

7.  The respiratory microbiome and susceptibility to influenza virus infection.

Authors:  Kyu Han Lee; Aubree Gordon; Kerby Shedden; Guillermina Kuan; Sophia Ng; Angel Balmaseda; Betsy Foxman
Journal:  PLoS One       Date:  2019-01-09       Impact factor: 3.240

Review 8.  Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters.

Authors:  Keiji Kuba; Yumiko Imai; Takayo Ohto-Nakanishi; Josef M Penninger
Journal:  Pharmacol Ther       Date:  2010-07-03       Impact factor: 12.310

Review 9.  Innate Immune Evasion by Human Respiratory RNA Viruses.

Authors:  Marjolein Kikkert
Journal:  J Innate Immun       Date:  2019-10-14       Impact factor: 7.349

10.  Covid-19 and Children with Immune Thrombocytopenia: Emerging Issues.

Authors:  Giuseppe Lassandro; Valentina Palladino; Viviana Valeria Palmieri; Anna Amoruso; Giovanni Carlo Del Vecchio; Paola Giordano
Journal:  Mediterr J Hematol Infect Dis       Date:  2020-05-01       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.